VolitionRx Ltd. (NYSE American: VNRX), a multi-national epigenetics company, has provided a consolidated update detailing recent clinical and commercial progress across its key diagnostic platforms. The company highlighted submission of a manuscript for peer review showcasing a new method, Capture-Seq, and new biomarkers for cancer detection, which it estimates represents an annualized total addressable market opportunity of approximately $23 billion.
Commercialization of the company's Nu.Q Cancer assay has progressed specifically in lung cancer. Volition reported that reimbursement submission in France is on track, with routine clinical use expected by the fourth quarter of 2026. This development is critical as it moves the test from research validation toward integration into standard healthcare pathways, potentially enabling earlier intervention for patients.
In parallel, Volition confirmed the inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France, aimed at the early detection of sepsis. The company also highlighted new clinical utility data for this assay in Hidradenitis Suppurativa, noting its CE-marked availability across Europe. The DETECSEPS program represents a significant validation of the technology's potential in a critical care setting where early diagnosis can dramatically impact survival rates. Further information on the company's broader efforts can be found at https://www.Volition.com.
The company reported breakthrough veterinary results, demonstrating 100% specificity in detecting feline lymphoma using its Nu.Q Vet Feline assay. Publication of this feline study is expected to unlock a $5 million contractual milestone payment, underscoring the commercial potential of the platform in animal health markets.
On the business development front, Volition confirmed ongoing licensing discussions with approximately 10 global diagnostic leaders and stated it anticipates announcing additional licensing agreements during 2026. Such partnerships are essential for scaling the distribution and implementation of its blood-based tests worldwide.
The progress across human and veterinary applications underscores a strategic expansion of epigenetics from research into practical, reimbursed clinical tools. The advancement of the Nu.Q assays toward routine use in France for lung cancer and their role in a major sepsis detection initiative highlight a tangible path to impacting patient care. Earlier detection of conditions like cancer and sepsis through simple blood tests could lead to more timely treatment, potentially improving survival rates and reducing healthcare costs associated with late-stage disease management. The company's focus on both a high-value human cancer market and validated veterinary applications demonstrates a diversified approach to commercializing its core epigenetic technology.
